Fight CRC Clinical Trial Finder
| NCT ID | Title | 阶段 | Date Added | 地点 | Prior IO Allowed | CRC-directed | Status | 药物 | 标签 |
|---|---|---|---|---|---|---|---|---|---|
| NCT ID NCT04730544 |
TitleEfficacy and Safety of Two Combination Treatment Regimens of Nivolumab and Ipilimumab in Patients With dMMR and / or MSI Metastatic Colorectal Cancer ( NIPISAFE ) | 阶段
第二阶段
|
Date Added 2021-01-29 |
地点
法国
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
Ipilimumab, Nivolumab |
标签
MSI-H/ MMRd
|
| NCT ID NCT04724239 |
TitleA Study of Sintilimab and Chidamide in Combination With or Without IBI305 in Standard Treatment Failure of Advanced or Metastatic pMMR/MSS Colorectal Carcinoma | 阶段
第二阶段
|
Date Added 2021-01-26 |
地点
中国
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
chidamide, IBI305, Sintilimab |
标签
MSS/ MMRp
|
| NCT ID NCT04708470 |
TitlePhase I/II Trial of the Combination of Bintrafusp Alfa (M7824), Entinostat and NHS-IL12 (M9241) in Patients With Advanced Cancer | 阶段
Phase 1, Phase 2
|
Date Added 2021-01-14 |
地点
Maryland, United States
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
Bintrafusp alfa, Entinostat, NHS-IL12 |
标签
MSS/ MMRp
|
| NCT ID NCT04687631 |
Title最初无法切除肝转移灶的 RAS/BRAF 野生型结直肠癌患者的转换疗法 | 阶段
第三阶段
|
Date Added 2020-12-29 |
地点
中国
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
招聘
|
药物
mFOLFOXIRI Plus Bevacizumab, mFOLFOXIRI plus Cetuximab |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT04660812 |
TitleAn Open Label Study Evaluating the Efficacy and Safety of Etrumadenant (AB928) Based Treatment Combinations in Participants With Metastatic Colorectal Cancer. | 阶段
Phase 1, Phase 2
|
Date Added 2020-12-09 |
地点
Alabama, United States
Arizona, United States California, United States Connecticut, United States District of Columbia, United States Georgia, United States Louisiana, United States Maryland, United States Missouri, United States Nevada, United States New York, United States Pennsylvania, United States South Carolina, United States Tennessee, United States Texas, United States Wisconsin, United States 法国 意大利 大韩民国 西班牙 英国 |
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
AB680, Bevacizumab, Etrumadenant, mFOLFOX-6 regimen, Regorafenib, Zimberelimab |
标签
MSS/ MMRp
|
| NCT ID NCT04659382 |
TitleStudy to Evaluate Efficacy and Safety of Selective Internal Radiation Therapy Plus Xelox, Bevacizumab and Atezolizumab (Immune Chekpoint Inhibitor) in Patients With Liver-dominant Metastatic Colorectal Cancer | 阶段
第二阶段
|
Date Added 2020-12-09 |
地点
法国
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
招聘
|
药物
Atezolizumab, Bevacizumab, TheraSphere, XELOX |
标签
MSS/ MMRp
|
| NCT ID NCT04653480 |
TitleSurufatinib, Toripalimab and Chemotherapy in Second-line MT and MSS CRC | 阶段
第二阶段
|
Date Added 2020-12-04 |
地点
中国
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
招聘
|
药物
Chemotherapy, Surufatinib, Toripalimab |
标签
MSS/ MMRp
|
| NCT ID NCT04626635 |
TitleREGN7075 in Combination With Cemiplimab in Adult Participants With Advanced Solid Tumors | 阶段
Phase 1, Phase 2
|
Date Added 2020-11-12 |
地点
California, United States
Florida, United States Illinois, United States Iowa, United States Massachusetts, United States Michigan, United States New Jersey, United States New York, United States Ohio, United States Pennsylvania, United States Tennessee, United States Texas, United States Wisconsin, United States 法国 以色列 荷兰 波兰 西班牙 Turkey |
Prior IO Allowed 是 |
CRC-directed 没有 |
Status
招聘
|
药物
cemiplimab, REGN7075 |
标签
MSS/ MMRp
|
| NCT ID NCT04607421 |
TitleA Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer (BREAKWATER) | 阶段
第三阶段
|
Date Added 2020-10-29 |
地点
Arizona, United States
California, United States Florida, United States Illinois, United States Louisiana, United States Minnesota, United States Missouri, United States Nebraska, United States New Jersey, United States New York, United States Ohio, United States Oklahoma, United States Oregon, United States Pennsylvania, United States Tennessee, United States Texas, United States Virginia, United States Washington, United States Wisconsin, United States 阿根廷 澳大利亚 比利时 巴西 Bulgaria 加拿大 中国 Czechia 丹麦 Finland 德国 India 意大利 日本 大韩民国 墨西哥 荷兰 新西兰 挪威 波兰 Russian Federation Slovakia 南非 西班牙 瑞典 台湾 Ukraine 英国 |
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
5-FU, Bevacizumab, capecitabine, cetuximab, encorafenib, Irinotecan, Leucovorin, oxaliplatin |
标签
MSS/ MMRp
|
| NCT ID NCT04599140 |
TitleSX-682和Nivolumab治疗RAS突变、MSS不可切除或转移性结直肠癌的STOPTRAFFIC-1试验 | 阶段
第 1 阶段
|
Date Added 2020-10-22 |
地点
Texas, United States
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
招聘
|
药物
CXCR1/2 Inhibitor SX-682, Nivolumab |
标签
MSS/ MMRp
|
